This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
National Vision (EYE) Store Openings Aid, Macro Issues Stay
by Zacks Equity Research
In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.
Reasons to Buy Prestige Consumer (PBH) Stock for Now
by Zacks Equity Research
Investors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio.
Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.
Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes
by Zacks Equity Research
Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.
Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures
by Zacks Equity Research
According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.
5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024
by Zacks Equity Research
Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.
Thermo Fisher (TMO) Unveils CorEvitas Pharmacovigilance Platform
by Zacks Equity Research
Thermo Fisher (TMO) introduces the CorEvitas pharmacovigilance platform for clinical research registries.
Haemonetics (HAE) Just Reclaimed the 200-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
Haemonetics (HAE) Just Overtook the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Penumbra (PEN) Stock Up 16.2% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), driven by growth in the vascular segments and upbeat guidance.
Thermo Fisher's (TMO) PPD Business Backs BARDA's Clinical Trial
by Zacks Equity Research
Thermo Fisher's (TMO) PPD clinical research business is selected by BARDA to support the Phase II platform clinical trial to treat ARDS.
Henry Schein (HSIC) Enters Orthopedic Market With New Buyout
by Zacks Equity Research
Henry Schein's (HSIC) recent deals will position it as a prominent producer and supplier in the orthopedic market's Foot and Ankle, Hand and Wrist extremity sectors.
Exact Sciences' (EXAS) Solid Cologuard Sales, Innovation Aid
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is offering therapy selection tests for patients with advanced cancer.
Myriad Genetics' (MYGN) New Platform to Advance Cancer Care
by Zacks Equity Research
Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.
Bruker (BRKR) Installs First 1.2 GHz NMR at Ohio University
by Zacks Equity Research
Bruker (BRKR) 1.2 GHz AVANCE NMR spectrometer is cutting-edge equipment capable of performing high-resolution liquid and solid-state NMR studies.
Bio-Rad (BIO) Faces Soft Industry-wide Demand, Macro Woes
by Zacks Equity Research
Bio-Rad's (BIO) margin performance suffers due to elevated raw material costs, increased logistics costs and higher employee-related expenses.
Venus Concept (VERO) Expands Global Reach With New Partnerships
by Zacks Equity Research
Venus Concept (VERO) expects its deals to fetch continued success in both the United Kingdom and India.
Quest Diagnostics (DGX) Unveils the 88-Compound NPS Test Panel
by Zacks Equity Research
Quest Diagnostics (DGX) launches the new 88-Compound NPS test panel to address the changing drug epidemic.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN), which is led by growth in vascular and neuro businesses.
Align's (ALGN) Invisalign Palatal Expander System Gets FDA Nod
by Zacks Equity Research
Align's (ALGN) Invisalign Palatal Expander is the company's first direct 3D-printed orthodontic device. It offers a safe, pleasant and clinically effective alternative to traditional palatal expanders.
CVS Health (CVS) New Opportunities Drive Growth, Macro Woes Stay
by Zacks Equity Research
CVS Health's (CVS) restructuring plan poises it well, along with its strategic buyouts.
SenesTech (SNES) Likely to Expand Into China With New Deal
by Zacks Equity Research
This partnership provides SenesTech (SNES) with a gateway into one of the largest pest control markets globally, with the support and expertise of Fruit Tree.